Conference Proceedings
Amfetamine and methylphenidate medications for attention-deficit/ hyperactivity disorder: Complementary treatment options
P Hodgkins, M Shaw, D Coghill, L Hechtman
European Child and Adolescent Psychiatry | SPRINGER | Published : 2012
Open access
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetaminebased stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies..
View full abstractGrants
Funding Acknowledgements
We thank Eric Southam of Oxford Pharma-Genesis Ltd for editorial assistance, collating of comments of authors, and editing the paper for submission. This editorial help was funded by Shire Development Inc., Wayne, PA, USA.Dr. Coghill has received speaker fees from Shire, Janssen Cilag, Medice, Lilly, UCB and Flynn Pharma; has served as a consultant or sat on advisory boards for Shire, Janssen Cilag, Shering-Plough, Pfizer, Lilly, Vifor and Flynn Pharma; has received research grants from Lilly, Janssen Cilag and Shire. Dr. Hechtman has served as a consultant or sat on advisory boards for Lilly, GlaxoSmith-Kline, Ortho Janssen, Purdue Pharma and Shire Canada and has received research grants from these companies. Dr. Hodgkins and Dr. Shaw are employees of Shire Pharmaceuticals or Shire PLC, respectively, and own stock in the company.